Acadia Pharmaceuticals Phase II Study of Pimavanserin in Alzheimer's Disease Meets Primary Endpoint of Psychosis Reduction.
M2 PHARMA-November 6, 2017-Acadia Pharmaceuticals Phase II Study of Pimavanserin in Alzheimer's Disease Meets Primary Endpoint of Psychosis Reduction
(C)2017 M2 COMMUNICATIONS
- San Diego, California-based central nervous system disorders therapeutics developer Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) presented data from its Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at a symposium at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston, the company said.
The Phase II -019 Study was a double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of pimavanserin in 181 patients with Alzheimer's disease psychosis.
Pimavanserin met the primary endpoint in the study, showing a statistically significant reduction in psychosis versus placebo as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH).
No detrimental effect was observed on cognition for pimavanserin-treated patients compared to placebo. Atypical antipsychotics have been associated with a statistically significant acceleration of cognitive deterioration in patients with Alzheimer's disease.
Data presented at CTAD from a pre-specified subgroup analysis demonstrated a substantively larger and significant reduction in psychosis in pimavanserin-treated patients with more severe psychosis, further underscoring the effect seen on the primary result.
Pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors thought to play an important role in dementia-related psychosis, is being evaluated in an extensive clinical development program by Acadia across multiple indications.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Nov 6, 2017|
|Previous Article:||Alexion Data Show 80% of Infants with LAL-D Treated with Kanuma (sebelipase alfa) Survive Beyond 1 Year of Age.|
|Next Article:||UroGen Pharma and Allergan enrol first patient in Phase 2 clinical trial of RTGel/BOTOX.|